Experimental immune cell therapy takes aim at childhood cancers

NCT ID NCT05238792

Recruiting now Disease control Sponsor: Children's National Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 05, 2026 · Updated 3 times

Summary

This early-stage study tests whether giving children with high-risk solid tumors a special type of immune cell (called TAA-T) is safe. The cells are designed to recognize and attack proteins found on tumor cells. Up to 36 children whose cancer has not responded to standard treatments will receive these cells, and researchers will monitor for side effects and any signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tumor-associated antigen-specific T cells (TAA-T)
What this could lead to: If successful, this could point toward a new immune-based treatment option for children with hard-to-treat solid tumors that have not responded to standard therapy.
What could go wrong: This is a very early Phase 1 safety trial with only 36 participants. The treatment may cause serious side effects like graft-versus-host disease or infusion reactions, and it is not yet known if it will shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ewing sarcoma neuroblastoma osteosarcoma rhabdomyosarcoma soft tissue sarcoma Wilms tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Children's National Hospital
RECRUITING

Washington D.C., District of Columbia, 20010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.